We use cookies to improve your experience on our website. Read about how we use cookies and how you can control them by reviewing the Cookie section of our Privacy Policy. By continuing to use this website, you consent to our use of these cookies.

close-icon

Log In to Bolder Science

Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Previous Next skip
Back

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

  • Clinicaltrials.gov identifier

    NCT04428788

  • Recruitment Status

    Recruiting

  • First Posted

    June 11, 2020

  • Last update posted

    August 18, 2022

Save Trial
Clinical Trial Information for Patients Visit BMS Study Connect

Study Description

Brief summary:

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

  • Condition or Disease:Prostatic Neoplasms
  • Intervention/Treatment: Drug: CC-94676
  • Phase: Phase 1

Detailed Description

N/A

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 122 participants
  • Intervention Model: Sequential Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
  • Actual Study Start Date: June 2020
  • Estimated Primary Completion Date: August 2023
  • Estimated Study Completion Date: February 2025

Arms and interventions

Arm Intervention/treatment
Experimental: Administration of CC-94676
 Drug: CC-94676
Specified dose on specified days

Outcome Measures

  • Primary Outcome Measures: 1. Maximum tolerated dose (MTD) [ Time Frame: Up to 35 days ]
  • 2. Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria [ Time Frame: From the time of consent at screening until 28 days after the subject discontinues study treatment. ]
  • 3. Dose-limiting toxicity (DLT) [ Time Frame: Up to 35 days ]
  • 4. Non-tolerated dose (NTD) [ Time Frame: Up to 35 days ]
  • Secondary Outcome Measures: 1. Confirmed Prostate Specific Antigen (PSA) decline of ≥ 50% from baseline (PSA50) [ Time Frame: Up to approximately 4 years ]
  • 2. Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) [ Time Frame: Up to approximately 4 years ]
  • 3. Duration of response (DOR) [ Time Frame: Up to approximately 4 years ]
  • 4. Proportion of participants alive and not progressed at 6 months [ Time Frame: Up to 6 months after treatment is discontinued ]
  • 5. PSA Progression Free Survival (PFS) [ Time Frame: Up to approximately 4 years ]
  • 6. Radiographic progression free survival (rPFS) [ Time Frame: Up to approximately 4 years ]
  • 7. Overall survival (OS) [ Time Frame: Up to approximately 4 years ]
  • 8. Overall Survival (OS) rate summarized using the Kaplan-Meier method for the treated population [ Time Frame: Up to approximately 4 years ]
  • 9. Pharmacokinetics - Area under the plasma concentration time curve (AUC) [ Time Frame: Up to 35 days ]
  • 10. Pharmacokinetics - Maximum plasma concentration (Cmax) [ Time Frame: Up to 35 days ]
  • 11. Pharmacokinetics - Time to Cmax (Tmax) [ Time Frame: Up to 35 days ]

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Male
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria: Must have histologically or cytologically confirmed adenocarcinoma of the prostate Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Exclusion Criteria: Prior treatment with an androgen receptor (AR) degrader Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP Clinically significant venous thromboembolism within 3 months prior to the first dose of IP Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply

Contacts and Locations

Contacts

Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com

Contact: First line of the email MUST contain the NCT# and Site #.

Locations

United States, Alabama
UAB
Birmingham

United States, California
Stanford University
Stanford

United States, Florida
M.D. Anderson Cancer Center
Orlando

United States, Florida
Florida Cancer Specialists
Sarasota

United States, Florida
Florida Cancer Specialists
Sarasota

United States, Georgia
Emory University.
Atlanta

United States, Illinois
University of Chicago
Chicago

United States, Maryland
Johns Hopkins
Baltimore

United States, Maryland
Johns Hopkins
Baltimore

United States, Massachusetts
Dana Farber Cancer Institute
Boston

United States, Massachusetts
Dana Farber Cancer Institute
Boston

United States, Michigan
University Of Michigan Cancer Center
Ann Arbor

United States, Michigan
START Midwest
Grand Rapids

United States, Michigan
START Midwest
Grand Rapids

United States, New York
Memorial Sloan-Kettering Cancer Center
New York

United States, New York
Mount Sinai - Icahn School of Medicine
New York

United States, New York
Mount Sinai Doctors Dermatology
New York

United States, New York
Columbia University
New York

United States, New York
Memorial Sloan Kettering cancer Center
New York

United States, North Carolina
Duke University Medical Center
Durham

United States, North Carolina
Duke University Medical Center
Durham

United States, Pennsylvania
Abramson Cancer Center
Philadelphia

United States, Pennsylvania
Abramson Cancer Center
Philadelphia

United States, Texas
UT Southwestern
Dallas

United States, Texas
Ut Southwestern
Dallas

United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio

United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio

United States, Washington
Fred Hutchinson Cancer Research Center
Seattle

United States, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison

United States, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison

United States, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison

Sponsors and Collaborators

Celgene

Investigators

Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

More Information

  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT04428788 History of Changes
  • Other Study ID Numbers: CC-94676-PCA-001, U1111-1251-9174
  • First Posted: June 11, 2020 Key Record Dates
  • Last Update Posted: August 18, 2022
  • Last Verified: August 2022

  • Individual Participant
    Data (IPD) Sharing
    Statement:

  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: Castration-resistant prostate cancer
    Adenocarcinoma of the prostate
    Prostatic Neoplasms Castration-Resistant     Prostate Cancer
    CC-94676
    Neoplasms
  • Additional relevant MeSH terms: Prostatic Neoplasms
    Neoplasms
    Genital Neoplasms, Male     Urogenital Neoplasms
    Neoplasms by Site
    Prostatic Diseases